MetaCap

IDEAYA Biosciences (IDYA) vs Pharvaris N.V. (PHVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharvaris N.V. (PHVS) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 26.0% versus a loss of 24.8%. Over five years, PHVS leads with a +131.3% price change compared with +7.3% for IDYA. IDEAYA Biosciences is the larger company by market cap ($2.47 billion vs $2.21 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%PHVS+25.98%
+61%+16%-29%
Nov 21, 20251 yearNov 20, 2026
IDYA+10.08%PHVS+100.90%
+156%+28%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus PHVS key metrics
MetricIDYAPHVS
Share price$25.56$31.28
Market cap$2.47B$2.21B
1-day change-2.33%-1.20%
YTD return-26.06%+12.72%
1-year return-24.80%+25.98%
5-year return+7.35%+131.28%
EPS (TTM)$-4.50$-3.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M—
Revenue growth (YoY)+3024.43%—
Net income (latest FY)$-113.70M$-25.99M
Operating margin-72.84%—
Net margin-51.99%—
52-week high$42.68$43.25
52-week low$25.46$23.15
Distance from 52-week high-40.11%-27.68%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+98.32%+86.29%
Average volume933.58K756.20K
Shares outstanding96.69M70.79M
Employees145168
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHVS has outperformed IDYA by 50.8 percentage points over the past year.

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Pharvaris N.V.

PHVS stock →

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

IDYA vs PHVS FAQ

Which is bigger, IDEAYA Biosciences or Pharvaris N.V.?

IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $2.47B compared with $2.21B for Pharvaris N.V. (PHVS).

Which stock has performed better over the past year, IDYA or PHVS?

PHVS returned +25.98% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and Pharvaris N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons